Bayesian Capital Management LP Takes $2.10 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Bayesian Capital Management LP acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 32,100 shares of the company's stock, valued at approximately $2,103,000.

A number of other hedge funds have also modified their holdings of AZN. Albion Financial Group UT grew its holdings in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after buying an additional 248 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after purchasing an additional 707 shares during the period. Crews Bank & Trust purchased a new position in AstraZeneca during the fourth quarter valued at approximately $55,000. Golden State Wealth Management LLC acquired a new position in AstraZeneca in the 4th quarter valued at approximately $55,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter valued at $55,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AZN stock traded up $0.27 on Friday, reaching $67.57. 6,215,921 shares of the company were exchanged, compared to its average volume of 5,141,616. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The stock's fifty day moving average price is $71.33 and its 200 day moving average price is $69.70. The firm has a market capitalization of $209.55 billion, a PE ratio of 29.90, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $2.06 earnings per share. On average, research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.